Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 2/20 | 0.76 |
| ▸ | PYGL | P06737 | 5/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17149781 | 0.90 | NHERF1 (0.88) | NHERF1PYGLHDAC3HDAC1HDAC2 | |
| SCHEMBL18766925 | 0.87 | NHERF1 (0.79) | NHERF1PYGLHDAC3HDAC1HDAC2 | |
| SCHEMBL17149767 | 0.85 | NHERF1 (0.80) | NHERF1PYGLHDAC3HDAC1HDAC2 | |
| SCHEMBL18750638 | 0.85 | NHERF1 (0.80) | NHERF1PYGLHDAC3HDAC1HDAC2 | |
| SCHEMBL17149780 | 0.84 | NHERF1 (0.73) | NHERF1PYGLHDAC3HDAC1HDAC2 | |
| SCHEMBL8182807 | 0.83 | NHERF1 (0.54) | NHERF1PYGLHDAC3HDAC1HDAC2 | |
| SCHEMBL25002623 | 0.83 | NHERF1 (0.76) | NHERF1PYGLHDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL8687321 | 0.82 | NHERF1 (0.53) | NHERF1PYGLHDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL8687837 | 0.81 | NHERF1 (0.52) | NHERF1PYGLHDAC3HDAC1HDAC2 | |
| SCHEMBL4276269 | 0.81 | HDAC1 (0.67) | HDAC3HDAC1HDAC2NAMPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2019-03-21 | — | — | US | disclosed |
| US-10167257-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| WO-2015150097-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD (GB) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | NHERF1 3852/4885PYGL 60/4885HDAC3 419/4885 |
| US-10167257-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | NHERF1 3785/4885PYGL 63/4885HDAC3 445/4885 |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | NHERF1 3785/4885PYGL 63/4885HDAC3 445/4885 |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | NHERF1 3748/4885PYGL 65/4885HDAC3 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.